ProPhase Labs (NASDAQ:PRPH) Announces Quarterly Earnings Results

ProPhase Labs (NASDAQ:PRPH) posted its quarterly earnings results on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.06, Zacks reports. ProPhase Labs had a negative return on equity of 62.92% and a negative net margin of 217.64%.

ProPhase Labs Stock Up 5.4%

PRPH stock traded up $0.02 during trading on Tuesday, hitting $0.34. 14,535,835 shares of the company’s stock were exchanged, compared to its average volume of 2,748,623. The business has a 50-day moving average price of $0.34 and a two-hundred day moving average price of $0.53. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $14.16 million, a price-to-earnings ratio of -0.27 and a beta of -0.47. ProPhase Labs has a 52-week low of $0.22 and a 52-week high of $5.45.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on ProPhase Labs in a report on Tuesday, February 25th. They issued a “sell” rating on the stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.